Mizuho Securities Sticks to Its Buy Rating for Avrobio Inc (AVRO)

By Austin Angelo

Mizuho Securities analyst Difei Yang reiterated a Buy rating on Avrobio Inc (AVROResearch Report) on August 9 and set a price target of $28. The company’s shares closed on Friday at $19.24.

According to TipRanks.com, Yang is a 4-star analyst with an average return of 5.4% and a 40.5% success rate. Yang covers the Healthcare sector, focusing on stocks such as Xeris Pharmaceuticals Inc, Alder Biopharmaceuticals, and Audentes Therapeutics.

Currently, the analyst consensus on Avrobio Inc is a Strong Buy with an average price target of $31.50, which is a 63.7% upside from current levels. In a report issued on August 9, H.C. Wainwright also maintained a Buy rating on the stock with a $35 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $53.70 and a one-year low of $11.85. Currently, Avrobio Inc has an average volume of 321.6K.

Based on the recent corporate insider activity of 9 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of AVRO in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Avrobio, Inc. engages in the development of lentiviral-based gene therapies. It focuses on gene therapy for fabry, gaucher, pompe disease, and cystinosis. These gene therapies, on which the company was founded, were developed by Dr. Jeffrey Medin and Dr. Christopher Paige at the University Health Network.